Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23484500 | 0.83 | HDAC8 (0.47) | SLC6A4RXRARXRBMAOB | |
| SCHEMBL22815981 | 0.82 | RHEB (0.49) | MRGPRX4SLC6A4RXRARXRBRXRG | |
| SCHEMBL22816302 | 0.80 | ALOX5 (0.48) | MRGPRX4SLC6A4PTPN1MAOB | |
| SCHEMBL9893908 | 0.80 | MRGPRX4 (0.51) | MRGPRX4RXRARXRBRXRG | |
| SCHEMBL2707432 | 0.79 | MRGPRX4 (0.52) | MRGPRX4RXRARXRB | |
| SCHEMBL8405629 | 0.78 | MAOB (0.47) | MRGPRX4PPARDPTPN1PTPN2PTPN6 | |
| SCHEMBL27621219 | 0.76 | PPARD (0.57) | MRGPRX4PPARDSLC6A4 | |
| SCHEMBL23484641 | 0.76 | XDH (0.46) | MRGPRX4MAOB | |
| SCHEMBL27458400 | 0.75 | MAOB (0.55) | MRGPRX4MAOB | |
| SCHEMBL3990183 | 0.74 | RXRA (0.68) | SLC6A4PTPN1PTPN2PTPN6RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | MRGPRX4 1196/4885PPARD 1756/4885SLC6A4 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.